Figure 2.
DLBCL patient samples exhibit low SMAD1 expression and high SMAD1 promoter hypermethylation. (A) Immunohistochemical SMAD1 staining of DLBCL patient samples derived from testis, lung, and lymph nodes, as well as a gastric marginal zone lymphoma (MZL) sample. Normal lymph nodes are shown as control. Scale bars, 100 μm. (B) Methylation analysis by bisulfite sequencing of region 2 within the SMAD1 promoter in DLBCL, MZL, normal B-cell, and lymph node samples. Each circle represents 1 CG dinucleotide. Each line represents 1 clone. Two or 3 clones were sequenced per sample. ●, methylated cytosine; ○, unmethylated cytosine; ×, aligned mismatches between genomic and bisulfite sequences. The red asterisk marks the patient sample that was further used for patient-derived xenotransplantation experiments in Figure 6.

DLBCL patient samples exhibit low SMAD1 expression and high SMAD1 promoter hypermethylation. (A) Immunohistochemical SMAD1 staining of DLBCL patient samples derived from testis, lung, and lymph nodes, as well as a gastric marginal zone lymphoma (MZL) sample. Normal lymph nodes are shown as control. Scale bars, 100 μm. (B) Methylation analysis by bisulfite sequencing of region 2 within the SMAD1 promoter in DLBCL, MZL, normal B-cell, and lymph node samples. Each circle represents 1 CG dinucleotide. Each line represents 1 clone. Two or 3 clones were sequenced per sample. ●, methylated cytosine; ○, unmethylated cytosine; ×, aligned mismatches between genomic and bisulfite sequences. The red asterisk marks the patient sample that was further used for patient-derived xenotransplantation experiments in Figure 6.

Close Modal

or Create an Account

Close Modal
Close Modal